Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
Usual gait speed over a short distance (commonly 4 meters) is a robust predictor of frailty, disability, hospitalization, and mortality. It is simple, reproducible, and widely used in geriatric assessment and rehabilitation follow-up. Slower speeds are associated with lower physiologic reserve and higher adverse-event risk.
Formula: Walking speed (m/s) = 4 / time(seconds).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Measure a straight, flat walking course of exactly 4 meters in a quiet, uncluttered area. Mark the start and finish lines clearly on the floor. For patients using walking aids, allow them to use their usual aid throughout the test — the presence of a walking aid should be noted in the documentation as it affects normative comparisons. The patient should be wearing their usual footwear. Instruct the patient to walk at their usual, comfortable pace — not faster or slower than normal — from the start line to the finish line.
Use a stopwatch to measure the time from when the patient's first foot crosses the start line to when their first foot crosses the finish line. Record time to the nearest 0.01 seconds. Calculate walking speed: gait speed (m/s) = 4 meters / time in seconds. For example, if a patient completes the walk in 5.0 seconds, their gait speed is 4 / 5.0 = 0.80 m/s. For reliability, perform 2 to 3 trials and average the results. Avoid rushing the patient or creating time pressure — the goal is usual walking pace, not maximum speed.
Interpret gait speed using established clinical thresholds: above 1.0 m/s is generally considered normal for community-dwelling older adults; 0.8 to 1.0 m/s indicates mild slowing with some increased risk; below 0.8 m/s indicates significantly slow gait associated with frailty, sarcopenia, fall risk, and adverse outcomes (EWGSOP2 sarcopenia criterion, Fried frailty phenotype criterion for slowness). Below 0.6 m/s indicates very slow gait with high risk of hospitalization and mortality. Serial measurements track response to exercise and rehabilitation interventions.
Geriatricians, sports medicine physicians, rehabilitation specialists
Gait speed below 0.8 m/s is one of the three core criteria for sarcopenia diagnosis under the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) guidelines, alongside low muscle mass and reduced muscle strength (grip strength). The 4-meter walk test is the preferred gait speed measurement method for clinical sarcopenia assessment. An abnormal gait speed triggers further evaluation with muscle mass measurement (DEXA, BIA) and grip strength testing. Identifying sarcopenia supports targeted resistance exercise programs, protein supplementation, and vitamin D optimization as evidence-based interventions.
Geriatricians, primary care physicians, nurse practitioners
Slow gait speed (below 0.8 m/s, adjusted for height and sex in the original Fried criteria) is one of the five Fried Frailty Phenotype criteria. The 4-meter walk test provides the physical performance component of this established frailty assessment framework. When combined with grip strength measurement, weight loss history, exhaustion assessment, and low physical activity assessment, the 4-meter gait speed allows complete Fried phenotype scoring. Gait speed is also a criterion in multiple other frailty definitions including FRAIL Scale and SOF.
Surgeons, anesthesiologists, cardiologists, cardiac surgeons
Gait speed is a powerful predictor of adverse outcomes after major surgery and cardiac procedures including coronary artery bypass, valve replacement, and transcatheter aortic valve implantation (TAVI). Patients with gait speed below 0.83 m/s before TAVI have significantly higher 1-year mortality, longer hospital stays, and lower rates of functional recovery. Pre-procedural 4-meter gait speed assessment takes less than 2 minutes and provides objective physical performance data that complements traditional cardiac risk scores (STS score, EuroSCORE). It is recommended in multiple cardiac surgery and TAVI guidelines for frailty screening.
Physiotherapists, physiatrists, rehabilitation nurses, occupational therapists
Serial 4-meter gait speed measurement is the gold standard outcome measure in geriatric rehabilitation, falls prevention programs, and exercise intervention studies. A clinically meaningful change threshold is approximately 0.05 to 0.10 m/s improvement from baseline, with larger changes (greater than 0.10 m/s) representing substantial functional gains. Documenting gait speed improvement over a rehabilitation course provides objective evidence of functional recovery for clinical documentation, insurance authorization, and program effectiveness reporting. In falls prevention, achieving gait speed above 1.0 m/s is associated with substantially reduced fall risk.
Neurologists, geriatric psychiatrists, primary care physicians
Gait speed is increasingly recognized as a biomarker of brain health and dementia risk. Slow gait speed predicts incident cognitive decline, dementia, and Alzheimer's disease in community-dwelling older adults, independent of traditional dementia risk factors. The link between gait and cognition reflects overlapping neural substrates — both gait control and executive function rely on prefrontal-basal ganglia networks. In clinical practice, combining gait speed assessment with cognitive screening tools provides a more complete brain health picture than cognitive testing alone. Gait speed decline preceding cognitive decline supports its role as an early brain aging biomarker.
Public health researchers, geriatric epidemiologists, clinical trialists
Large prospective studies, including the landmark 2011 Studenski et al. JAMA paper pooling data from 34,485 patients, demonstrated that gait speed predicts survival more accurately than age, sex, body mass index, and chronic conditions alone. Gait speed is now considered a vital sign of aging and is used in large-scale epidemiological studies of healthy aging, disability trajectories, and longevity. Its continuous measurement properties make it sensitive to detecting small intervention effects in clinical trials, making the 4-meter walk test one of the most commonly used functional outcome measures in geriatric and sarcopenia research.
The 4-meter walk test measures habitual or comfortable walking speed — the pace the patient actually uses in daily life. Instructing the patient to walk 'as fast as safely possible' measures maximum speed, which has different normative values and clinical implications. Always specify 'walk at your normal, usual pace' before the test. Usual speed reflects daily functional capacity and predicts outcomes better than maximum speed for most clinical applications.
While multiple thresholds exist in the literature, 0.8 m/s is the most widely used and validated clinical cut-point for identifying slow gait associated with frailty, sarcopenia (EWGSOP2), increased fall risk, and adverse outcomes. Below 0.8 m/s should trigger further evaluation for sarcopenia, frailty, fall risk, and reversible contributors to gait slowing (pain, deconditioning, medication effects, vitamin D deficiency).
Always document whether the patient used a walking aid during the test (none, cane, walker, rollator). Normative gait speed values differ between aid-users and non-users. Patients using walking aids have lower average gait speeds that reflect both the underlying functional limitation that led to aid adoption and the mechanical constraints of the device. Serial comparisons should be made with consistent aid use.
In standard protocol, timing starts when the patient's first foot crosses the start line (after the patient has accelerated to comfortable walking speed) and stops when the first foot crosses the finish line (before deceleration). Some protocols include 1 to 2 meter acceleration and deceleration zones before and after the 4-meter timed section to eliminate speed variation artifacts. Whichever protocol you use, apply it consistently for valid serial comparisons.
A change of approximately 0.10 m/s in gait speed represents a clinically meaningful difference in community-dwelling older adults — equivalent to a meaningful change in functional ability and daily life independence. Exercise interventions that improve gait speed by 0.10 m/s or more have been shown to reduce fall risk and improve community mobility. Track serial gait speed measurements to document treatment response in rehabilitation and frailty management programs.
The Studenski meta-analysis demonstrated that gait speed predicts 5-year and 10-year survival better than age alone. Among 70-year-olds with gait speed above 1.0 m/s, most are predicted to survive 10 or more years; among those with gait speed below 0.4 m/s, most have very limited predicted survival. This relationship holds across age groups, supporting gait speed as a true biomarker of biological aging rather than a simple reflection of chronological age.
EWGSOP2 sarcopenia diagnosis requires evidence of reduced muscle strength (typically assessed by grip dynamometry) plus evidence of low muscle mass (DEXA or BIA). Gait speed below 0.8 m/s confirms severe sarcopenia when muscle mass is also reduced. If grip strength is normal but gait speed is slow, consider neurological contributors (Parkinson's, peripheral neuropathy), pain, or deconditioning as alternative explanations before concluding sarcopenia.
Acute or chronic pain from hip or knee arthritis, plantar fasciitis, lumbar stenosis, or other orthopedic conditions can substantially slow gait speed independently of frailty or sarcopenia. When interpreting gait speed in a patient with significant pain, document the pain level and location and consider whether pain management could improve gait speed before concluding that the slow speed reflects irreversible physical decline.
Gait speed is increasingly recommended as a routine geriatric vital sign — a quick functional assessment that should be obtained at every geriatric visit alongside blood pressure, heart rate, and weight. Its predictive power for hospitalization, disability, and mortality makes it one of the most informative single measurements available in geriatric medicine. Documenting baseline gait speed and tracking trends over time provides longitudinal functional insight that supplements traditional vital signs.
Gait speed is a validated functional vital sign; speeds below roughly 0.8 m/s are commonly associated with increased adverse-outcome risk.
Lower gait speeds suggest reduced mobility reserve and higher frailty/disability risk, supporting fall-prevention and rehabilitation-focused care planning.
Use in older-adult screening, rehab follow-up, preoperative assessment, and longitudinal function monitoring.
Performance can be affected by temporary pain, footwear, environment, and assistive-device use; test conditions should be standardized for trend comparisons.
For related assessments, see Timed Up and Go, SPPB Score and 5x Sit-to-Stand.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Assess mobility and fall risk with the Timed Up and Go (TUG) test. TUG >12 seconds indicates high fall risk. Times the performance of standing, walking 3 meters, turning, and returning to seated.
OpenGeriatricsEstimate lower-extremity functional performance with SPPB total score (0-12) from balance, gait speed, and chair stands.
OpenGeriatricsAssess lower-extremity functional strength and mobility by timing 5 repeated chair stands.
OpenGeriatricsScreen frailty using the 5-item FRAIL scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of weight).
Open